Daiwa Securities Group Inc. - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 325 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$340
+32.3%
2,803
+24.7%
0.00%0.0%
Q2 2023$257
-11.7%
2,247
+6.6%
0.00%0.0%
Q1 2023$291
-32.9%
2,107
-37.1%
0.00%
-33.3%
Q4 2022$434
-99.9%
3,349
+1.2%
0.00%0.0%
Q3 2022$366,000
+44.1%
3,310
-2.4%
0.00%
+50.0%
Q2 2022$254,000
-10.6%
3,391
-6.8%
0.00%0.0%
Q1 2022$284,000
-13.9%
3,639
-0.7%
0.00%0.0%
Q4 2021$330,000
-13.6%
3,666
-11.3%
0.00%
-33.3%
Q3 2021$382,000
+23.2%
4,133
+3.5%
0.00%
+50.0%
Q2 2021$310,000
-39.1%
3,992
-41.6%
0.00%
-50.0%
Q1 2021$509,000
-57.6%
6,833
-2.9%
0.00%
-55.6%
Q4 2020$1,200,000
+8.5%
7,034
-10.7%
0.01%
-10.0%
Q3 2020$1,106,000
+180.7%
7,876
-10.3%
0.01%
+25.0%
Q2 2020$394,000
-54.2%
8,7850.0%0.01%
-11.1%
Q1 2020$860,000
-25.7%
8,785
-2.1%
0.01%
-10.0%
Q4 2019$1,158,000
+68.8%
8,971
-1.6%
0.01%
+66.7%
Q3 2019$686,000
-32.0%
9,120
+37.4%
0.01%
-33.3%
Q2 2019$1,009,000
+23.5%
6,639
-3.2%
0.01%
+28.6%
Q1 2019$817,000
+2.8%
6,855
-5.9%
0.01%
-12.5%
Q4 2018$795,000
+1270.7%
7,282
+1939.8%
0.01%
Q3 2018$58,000
+23.4%
3570.0%0.00%
Q2 2018$47,000
+80.8%
3570.0%0.00%
Q1 2018$26,0003570.00%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Perceptive Advisors 2,878,979$69,182,0007.27%
Eventide Asset Management 259,100$6,226,0000.97%
GLADE BROOK CAPITAL PARTNERS LLC 251,000$6,032,0000.93%
IMS Capital Management 32,215$774,0000.91%
Perceptive Advisors 350,000$8,413,0000.88%
Benchmark Capital Advisors 34,900$839,0000.58%
BECK CAPITAL MANAGEMENT, LLC 24,744$636,0000.49%
SABBY MANAGEMENT, LLC 352,100$8,461,0000.47%
Hatteras Alternative Mutual Funds, LLC 39,404$947,0000.46%
Potomac Capital Management, Inc. 22,100$531,0000.45%
View complete list of SAREPTA THERAPEUTICS INC shareholders